Baseline Assessment

Return to Enrollment Page

Primary Audience:

This activity is intended to meet the educational needs of neurologists and neurology APPs (NPs, PAs) involved in the management of patients with CIDP.

OVERVIEW

Answer the questions to gauge your current knowledge of CIDP: diagnosis and workup, evidence for and use of subcutaneous therapies, and use of corticosteroids.

FACULTY

Brett Morrison, M.D., Ph.D.

Associate Professor of Neurology
Division of Neuromuscular Medicine
Program Director of Neuromuscular Medicine Fellowship
Director of Inpatient Neurology Consult Service
Johns Hopkins School of Medicine
Baltimore, MD

Dr. Brett Morrison specializes in neuromuscular disorders in adults including amyotrophic lateral sclerosis, motor neuropathies, myasthenia gravis and muscle diseases including myopathy and muscular dystrophy.

Dr. Morrison’s research interests include investigations into the basic mechanisms of acute denervation and the development of treatments for chronic denervating diseases such amyotrophic lateral sclerosis or motor neuropathies. Current research focuses on treatments designed to reduce muscle loss and atrophy, and thus preserve function, following denervation.

Dr. Brett Morrison received his M.D. and Ph.D. from Mount Sinai Medical School in New York City. He completed his medical internship at the University of Maryland and residency in neurology at The Johns Hopkins Hospital.

LEARNING OBJECTIVES

1.
Apply knowledge of the workup (including EMG interpretation) and diagnostic criteria to differentiate CIDP from other immune-mediated neuropathies.
2.
Use evidence, guideline recommendations, and expert guidance to the use of subcutaneous agents to personalize maintenance therapy for CIDP.
3.
Differentiate clinical scenarios in which corticosteroids are beneficial, contraindicated, or inferior to alternative therapies in CIDP.